NCT06288932View on ClinicalTrials.gov

Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopenia Purpura.

PHASE3CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

February 18, 2024

Study Completion Date

August 18, 2024

Conditions

Immune Thrombocytopenia Purpura

Interventions

DRUG

Mycophenolate Mofetil (MMF) Treatment

The first-line treatment of immune thrombocytopenia purpura with Mycophenolate Mofetil produced a significant response, a lowered likelihood of refractory ITP, a better outcome, and less financial burden.

Trial Locations (1)

75300

National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi

All Listed Sponsors

lead

National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

OTHER_GOV